Prolia (Denosumab) Off-Label Uses With Evidence Levels

How Denosumab Works: The RANKL Pathway

Denosumab is a fully human IgG2 monoclonal antibody that binds receptor activator of nuclear factor kappa-B ligand (RANKL) with high affinity and specificity. By sequestering RANKL before it can engage its receptor RANK on osteoclast precursors, the drug blocks osteoclast differentiation, activation, and survival in a single step [1]. This produces a rapid, reversible suppression of bone resorption.

Within 12 hours of a 60 mg subcutaneous injection, serum C-telopeptide (CTX), a bone-resorption marker, drops by roughly 85% [2]. That suppression persists for approximately five to six months before gradually wearing off, which is precisely why the drug is dosed every 26 weeks in the osteoporosis setting. The reversibility distinguishes denosumab from bisphosphonates, which embed in the bone matrix and suppress resorption for months to years after the last dose.

This clean on-off pharmacology explains both the drug's appeal and its primary risk. Stopping denosumab without a bisphosphonate bridge allows a rapid rebound in bone turnover markers, sometimes exceeding pretreatment levels, that can trigger multiple vertebral compression fractures within 7 to 12 months of the last injection [3]. Every off-label application discussed below must be weighed against this discontinuation hazard.

The RANKL pathway also operates outside bone. RANKL signaling influences dendritic cell survival, lymph node organogenesis, and mammary gland development during pregnancy [1]. These broader biological roles underpin several of the off-label hypotheses, particularly in oncology, while also flagging potential immune-related adverse effects during long-term use.

On-Label Anchors: What the FDA Actually Approved

Before cataloging off-label uses, it helps to define the boundaries of the label. The FDA has approved denosumab under two brand names at two different doses for distinct patient populations [4].

Prolia (60 mg SC every 6 months) carries indications for postmenopausal women with osteoporosis at high fracture risk, bone loss in men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer, bone loss in women receiving aromatase inhibitor (AI) therapy for breast cancer, glucocorticoid-induced osteoporosis in patients at high fracture risk, and men with osteoporosis at high fracture risk [4]. Xgeva (120 mg SC every 4 weeks) is indicated for prevention of skeletal-related events in patients with bone metastases from solid tumors and for giant cell tumor of bone (GCTB) in adults and skeletally mature adolescents when surgical resection would cause severe morbidity [5].

Any prescription that falls outside these exact populations, doses, or conditions is off-label. The Endocrine Society's 2020 clinical practice guideline notes: "Denosumab may be considered for patients who cannot tolerate oral bisphosphonates or who have significant renal impairment (eGFR <30 mL/min), where zoledronic acid is contraindicated" [6]. That recommendation stretches beyond the narrow FDA label and illustrates how consensus guidelines already endorse broader use.

Off-Label Use 1: Glucocorticoid-Induced Osteoporosis Beyond the Label

Denosumab received a Prolia label expansion for glucocorticoid-induced osteoporosis (GIO) in 2018, but many rheumatologists had been prescribing it off-label for years before that. The reason: patients on chronic prednisone who failed or could not tolerate bisphosphonates had few alternatives.

The key GIO data came from two randomized, double-blind trials comparing denosumab 60 mg every 6 months against risedronate 5 mg daily. In the GIO-continuing study (N=505), patients already on glucocorticoids for at least 3 months gained 3.8% lumbar-spine BMD at 12 months with denosumab vs. 0.8% with risedronate [7]. The GIO-initiating study (N=795) enrolled patients beginning glucocorticoid therapy and showed lumbar BMD gains of 3.8% vs. 0.2% at 12 months [7].

Where the off-label territory begins: many clinicians now use denosumab as first-line GIO therapy in patients with eGFR <30 mL/min, where both oral and IV bisphosphonates are contraindicated or require extreme caution. This renal-impairment niche is not explicitly on-label, yet it is supported by expert consensus in the 2022 American College of Rheumatology GIO guideline [8]. Hypocalcemia risk rises sharply in CKD stage 4-5, so calcium and 25-hydroxyvitamin D levels must be corrected before the first injection.

Off-Label Use 2: Hypercalcemia of Malignancy Refractory to Bisphosphonates

Bisphosphonate-refractory hypercalcemia of malignancy (HCM) is a medical emergency with limited options. Denosumab 120 mg SC has become a go-to rescue agent despite never receiving an FDA indication for HCM.

The evidence base rests on two open-label, single-arm studies (N=33 and N=82) that enrolled patients with persistent hypercalcemia (corrected serum calcium ≥12.5 mg/dL) after IV zoledronic acid. In the pooled analysis, 64% of patients achieved corrected calcium ≤11.5 mg/dL within 10 days of the first denosumab injection, with a median duration of response of 104 days [9]. Dr. Mimi I. Hu of MD Anderson Cancer Center, the lead investigator, stated: "Denosumab provided clinically meaningful and durable calcium reduction in patients who had exhausted bisphosphonate options" [9].

The NCCN Clinical Practice Guidelines in Oncology now list denosumab as a category 2A recommendation for bisphosphonate-refractory HCM [10]. Dosing follows the Xgeva skeletal-event schedule: 120 mg SC on days 1, 8, 15, and 29, then every 4 weeks. Severe hypocalcemia is the primary risk, reported in up to 9% of patients, and daily calcium plus vitamin D supplementation is mandatory.

Off-Label Use 3: Giant Cell Tumor of Bone in Surgical Candidates

Xgeva holds an FDA approval for unresectable GCTB. The off-label frontier involves using denosumab as neoadjuvant downsizing therapy before planned curettage or resection, aiming to reduce surgical morbidity and enable joint-sparing procedures.

In a phase II open-label study (N=532), Chawla et al. reported that 96% of surgically unsalvageable GCTB patients had no disease progression at a median follow-up of 13 months on denosumab 120 mg SC every 4 weeks [11]. Among 260 patients initially deemed to need surgery, 38% had their planned procedure either avoided or downstaged after denosumab pretreatment [11]. Tumor response manifested as peripheral ossification and reduced soft-tissue mass on CT, often within 3 to 6 months.

The controversy centers on recurrence. A 2019 systematic review of 881 patients found local recurrence rates of 20 to 44% after curettage following denosumab compared with 12 to 25% for curettage alone [12]. The leading hypothesis: denosumab induces a hard peripheral shell that obscures the tumor-bone interface, making complete intralesional excision more difficult. Surgeons considering this approach must weigh the reduced morbidity of a smaller resection against the potentially higher recurrence rate.

Off-Label Use 4: Aneurysmal Bone Cysts

Aneurysmal bone cysts (ABCs) share molecular overlap with giant cell tumors. Both lesions overexpress RANKL, which drives the osteoclastic bone destruction responsible for cyst expansion. This shared biology provided the rationale for off-label denosumab trials in ABCs [13].

A 2020 multicenter retrospective study of 14 pediatric and young adult patients with surgically challenging ABCs reported complete or partial radiographic response in 12 of 14 patients (86%) after a median of 12 months of denosumab therapy [13]. Pain resolution occurred in all responders within 4 weeks. Two patients experienced rebound cyst growth after discontinuation, mirroring the post-denosumab rebound phenomenon seen in osteoporosis.

Dose heterogeneity remains a problem. Published pediatric regimens range from 1 mg/kg to the full adult Xgeva dose of 120 mg SC every 4 weeks, and no randomized trial has established optimal dosing or duration. The Pediatric Orthopedic Society of North America does not yet include denosumab in its ABC management guidelines, though the 2023 expert consensus from the French Sarcoma Group endorsed a trial of denosumab for ABCs in locations where surgery would cause significant growth-plate damage or neurological compromise [14].

Off-Label Use 5: Periprosthetic Bone Loss After Joint Replacement

Periprosthetic bone loss after total hip or knee arthroplasty accelerates implant loosening and raises revision surgery risk. Bisphosphonates have shown modest protective effects, but denosumab's more complete resorption suppression makes it an attractive alternative.

A 2021 randomized controlled trial from Seoul National University Hospital (N=92) compared denosumab 60 mg SC at surgery and 6 months post-op against placebo in patients receiving cementless total hip arthroplasty. At 12 months, periprosthetic BMD in Gruen zones 1 and 7 (the regions most prone to stress shielding) was 7.2% higher in the denosumab group (P<0.01) [15]. The placebo group lost an average of 6.8% periprosthetic BMD in zone 7, while the denosumab group gained 0.4%.

This remains a small, single-center trial. No regulatory body or orthopedic society has endorsed denosumab for this indication, and the discontinuation rebound effect raises questions about what happens to the preserved bone once injections stop. A multicenter trial (ClinicalTrials.gov NCT04637789) is currently enrolling to answer these questions with 3-year follow-up.

Off-Label Use 6: Pediatric Osteogenesis Imperfecta

Osteogenesis imperfecta (OI) is a genetic disorder of collagen synthesis causing fragile bones, most commonly managed with cyclic IV pamidronate in childhood. Denosumab entered the picture because children with severe OI (types III and IV) often plateau on bisphosphonate therapy after 2 to 4 years.

A crossover study at the Shriners Hospital for Children (N=10, ages 5-16) switched children from IV pamidronate to denosumab 1 mg/kg SC every 12 weeks. Lumbar spine areal BMD Z-scores improved by +0.5 SD over 48 weeks, and urinary N-telopeptide fell by 78% within 2 weeks of each injection [16]. Fracture rates decreased from a mean of 2.8 per year on pamidronate to 1.0 per year on denosumab, though the sample was too small for statistical significance.

The pediatric concern is growth-plate disruption. RANKL signaling participates in endochondral ossification, and animal models have shown widened, disorganized growth plates with prolonged RANKL inhibition [17]. A 2023 review in the Journal of Bone and Mineral Research cautioned: "Denosumab use in growing children requires careful monitoring of linear growth velocity, growth-plate morphology on MRI, and serum calcium, ideally within a clinical trial framework" [17]. No pediatric formulation exists, and dosing remains empirical.

Off-Label Use 7: Medication-Related Osteonecrosis of the Jaw Prevention During Drug Holidays

Medication-related osteonecrosis of the jaw (MRONJ) occurs in approximately 1 to 9% of cancer patients receiving high-dose denosumab (120 mg monthly) and in roughly 0.04% of osteoporosis patients on Prolia [18]. When invasive dental procedures are needed, clinicians face a dilemma: stopping denosumab risks rebound vertebral fractures, while continuing it may raise MRONJ risk at the surgical site.

An emerging off-label strategy involves timing dental procedures during the window of declining resorption suppression, roughly 5 to 6 months after the last Prolia injection, and delaying the next dose by 4 to 8 weeks. This "dental window" approach lacks randomized data but draws support from a 2022 retrospective cohort (N=142) that reported zero MRONJ cases when tooth extractions were performed 5 to 7 months after the last Prolia injection, vs. 2 cases (2.1%) when extractions occurred within 3 months [19].

The American Association of Oral and Maxillofacial Surgeons 2022 position paper acknowledges this timing strategy as "reasonable in the osteoporosis setting" but stops short of formal endorsement, citing insufficient prospective evidence [20].

Off-Label Use 8: Paget Disease of Bone Refractory to Bisphosphonates

Paget disease of bone is typically controlled with a single 5 mg IV infusion of zoledronic acid, which normalizes serum alkaline phosphatase (ALP) in over 95% of patients. The rare patient who fails zoledronic acid or cannot receive it (eGFR <35 mL/min) poses a therapeutic challenge.

Case reports and small series totaling approximately 30 patients describe denosumab 60 mg SC every 6 months normalizing ALP within 3 months in bisphosphonate-refractory Paget disease [21]. The largest published series (N=12) from the University of Oxford demonstrated median ALP reduction of 74% at 6 months, with all patients achieving at least partial biochemical response [21]. Pain scores improved in 10 of 12 patients.

Duration of therapy is undefined. Unlike zoledronic acid, which provides years of remission after a single dose, denosumab's reversible mechanism means Paget disease will likely reactivate after discontinuation. Long-term cyclic denosumab may be necessary, introducing cumulative MRONJ and atypical fracture risks that have not been studied in this population.

Evidence-Level Summary

The off-label uses described here span a wide evidence range. Cancer treatment-induced bone loss in the ADT and AI settings carries the strongest data (phase III RCTs, guideline-endorsed), though these indications are now partially on-label for Prolia. Bisphosphonate-refractory hypercalcemia of malignancy sits at the phase II / guideline-recommended level (NCCN category 2A). Giant cell tumor downsizing and aneurysmal bone cyst management rest on phase II and retrospective data. Periprosthetic bone loss, pediatric OI, Paget disease, and the MRONJ dental-window strategy depend on small RCTs, retrospective cohorts, or case series.

Clinicians considering any off-label denosumab prescription should document the evidence level in the medical record, confirm adequate calcium and vitamin D status, counsel the patient on rebound fracture risk at discontinuation, and plan an exit strategy (typically transition to an oral or IV bisphosphonate) before writing the first prescription [3]. Baseline serum 25-hydroxyvitamin D should be ≥30 ng/mL, and corrected calcium should be within normal range before each injection.